酒精性肝病诊疗指南（2006年2月修订）.pdfVIP

268 现代消化及介入诊疗 2007年 第12卷 第4期 Modem DigestionIntervention 2007，Vo1．12，No．4 Association for the Study of Liver Diseases(AASLD)． Chronic diatric nonalcoholic fatty liver disease．Hepatology 2005；42：641- hepatitis B：update of recommendations．Hepatology 2004；39：857— 649． 861． ． 1l Farrell GC，George J，Pauline MH，McCullough AJ，eds．Fatty liver 2 Farrell GC，George J，Pauline de la M．Hall and McCullo．ugh AJ， diseas：NASH and related disorders．Oxford：Blackwell Publishing eds． Faay liver disease： NASH and related disorders． Oxford： 2005：159-207． Blackwell Publishing 2005：1-22． 12 Neuschwander-Tetri BA，Caldwell SH．Nonalcoholic steatobepati- 3 American Gastroenterological Association．AnleHcart Gastroentero- tis：summary of art AASLD Single Topic Conference．Hepatology logical Association medical position statement： nonalcoholic fatty 2003；37：1202-1219． liver disease．Gastroenterology 2002；123：1702-1704． 13 Angulo P．Nonalcoholic fatty liver disease．N Engl J Med 2002；346： 4 中华医学会肝病学分会脂肪肝和酒精性肝病学组．非酒精性脂肪 1221-1231． 性肝病诊断标准．中华肝脏病杂志 2003；l1：71． 14 Ghali P，Lindor KD．Hepatotoxicity of drugs used for treatment of 5 Sanyal AJ．AGA technical review on nonalcoholic fatty liver dis- obesity and its comorbidities．Semin Liver Dis 2004；24：389-397． ease．Gastroenterology 2002；123：1705-1725． 15 Harrison SA，Torgerson S，Hayashi P，et a1．Vitamin E and vitamin 6 Ramesh S，Sanyal AJ．Evaluation and management of non-alcoholic C treatment improves fibrosis in patients with nonalcoholic steato- steatohepatitis．J Hepatol 2005；42：$2-S12． hepatitis．Am J Gastroenterol 2003；98：2485-2490． 7 Eckel RH， Grundy SM， Zimmet PZ． The metabolic syndrome． 16 Angulo P．Use of ursodeoxycholic acid in patients with liver disease． Lancet 2005；365：1415-1428． Curr Gastroen